Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463320 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00463320 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 29 participants.
The verdict
NCT00463320, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a two-part study to evaluate the safety, tolerability and pharmacokinetics of single (Part A) and repeat (Part B) eye drop doses of pazopanib in healthy adult and elderly subjects.
Interventions
- DRUG Pazopanib eye drops and Allergen Refresh Plus eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00463320
The ClinicalTrials.gov registry entry for NCT00463320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib eye drops and Allergen Refresh Plus eye drops is the first listed.
NCT00463320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00463320 about?
NCT00463320 is a clinical study titled "A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.". This is a two-part study to evaluate the safety, tolerability and pharmacokinetics of single (Part A) and repeat (Part B) eye drop doses of pazopanib in healthy adult and elderly subjects.
What is the current status of trial NCT00463320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2007-03. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00463320?
The interventions under investigation include: Pazopanib eye drops and Allergen Refresh Plus eye drops (DRUG).
Who is sponsoring clinical trial NCT00463320?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.